AlphAIalphai — Financial news for AI agents
BenzingaOCT 233 min read$NEON

Top 3 Tech Stocks That Could Lead To Your Biggest Gains In October - Neonode (NASDAQ:NEON), American Bitcoin (NASDAQ:ABTC)

The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

Original reporting
Benzinga · Avi Kapoor
Published Oct 23, 2025, 10:20 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 23, 2025, 10:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Top 3 Tech Stocks That Could Lead To Your Biggest Gains In October - Neonode (NASDAQ:NEON), American Bitcoin (NASDAQ:ABTC) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$NEONBearishMed
01

Why it matters

While some stocks show technical signs of rebound, overall market conditions and external factors could limit gains. Traders should exercise caution and consider technical confirmation before acting.

02

Market read

The news emphasizes short-term trading opportunities in select tech stocks and cryptocurrencies based on technical indicators, with a focus on RSI signals.

03

What to watch

Market volatility, upcoming earnings reports, and macroeconomic factors could override technical signals and influence stock movements.

Timing: Short-term (next 2-4 weeks)

Background

The article discusses oversold stocks in the technology sector, highlighting potential buying opportunities based on RSI momentum indicator.

Company-level read

Ticker impact

$NEONBearishMedium confidence
Context

The article highlights Neonode (NASDAQ:NEON) as one of the top tech stocks with potential gains in October, citing its oversold status based on RSI indicator.

Expected impact

Moderate upward correction expected within the next 2-4 weeks.

Evidence & confidence

The RSI indicates oversold conditions, suggesting a potential rebound; however, limited technical data and market volatility introduce uncertainty.

Market effects

Sector

The focus on undervalued tech stocks may boost sector sentiment temporarily, but overall impact is limited.

Regional

Primarily US-based stocks; limited regional effects expected.

Global

Low; the news pertains mainly to US tech stocks and cryptocurrencies with minimal global influence.

Counterpoint

What could challenge this read

The oversold condition may persist or worsen if broader market sentiment remains negative; potential for further declines in Neonode and other tech stocks.

Key entities

  • Company
    Neonode

    A technology company specializing in touch and sensor solutions.

  • Cryptocurrency
    Bitcoin

    A decentralized digital currency operating on blockchain technology.

Read at source← All news

Related articles

AUG 12
$NEONMed

Neonode Inc. (NEON): Results of Operations and Financial Condition

Neonode Inc. (NEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_975142.htm EXHIBIT 99.1 ex_975142.htm Exhibit 99.1 Press Release For Release, 9:10AM ET August 12, 2026 Neonode Reports Quarter Ended June 30, 2026 Financial Results STOCKHOLM, SWEDEN, August 12, 2026 — Neonode Inc. (NASDAQ: NEON) (“Neonode” or the “Company”) today r

SEC EDGAR 8-K4 min
AUG 12
$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

finanznachrichten.de4 min
AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 12
$FGLMed

Founder Group Limited Secures Second Aquaculture Contract, a US$1.4 million 1.78 MW rooftop system for a Kedah shrimp Farm

Founder Group Limited (NASDAQ: FGL) said its subsidiary Founder Energy Sdn Bhd signed a turn-key EPCC contract for a 1.78 MW-peak rooftop solar system for a shrimp farming and processing facility in Ayer Hitam, Kedah. The contract is valued at about RM5.58 million (US$1.37 million). The company also cited Malaysia RE policy targets and plans for 25-year operations.

thestarphoenix.com4 min